Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

MHLW Relied On EU and U.S. For Actos Safety Data, But Newly Funded Health Records Database Will Boost Japan's Pharmacovigilance

This article was originally published in PharmAsia News

Executive Summary

TOKYO - Japan's Ministry of Health, Labor and Welfare followed the lead of EMA and U.S. FDA and requested Takeda Pharmaceutical Co. Ltd. to change labeling for Actos (pioglitazone) to reflect safety concerns about the risk of bladder cancer. MHLW had to rely on epidemiological data compiled by EMA, but MHLW's safety division hopes new funding from the government will help build an electronic health records database to conduct similar pharmacovigilance epidemiology studies for the Japanese market

You may also be interested in...



Japanese Government to Tackle Preventative Health Care Using Big Data

In an effort to curb soaring medical costs for social services, Prime Minister Shinzo Abe's growth strategy has included plans to use big data for preventative health care.

Rethinking Sources Of Innovation In Asia As The “Pendulum Swings Back” To Japan – BIO Asia

Companies like Merck Serono, AstraZeneca and Eisai are reshuffling R&D operations in Asia to capitalize on new hubs of innovation.

Japan's Generic Market Primed For Growth, But Distribution And Manufacturing Barriers Remain

Substantial patent expirations in the next few years and government incentives for generic use make Japan's generic market ideal for midterm growth, but stringent API standards and complex distribution channels have left some foreign firms in a difficult spot.

Related Content

UsernamePublicRestriction

Register

LL1129367

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel